samedan logo
 
 
 
spacer
home > ebr > autumn 2021 > bio-europe foreword
PUBLICATIONS
European Biopharmaceutical Review

BIO-Europe Foreword

BIO-Europe is pleased, for the second year, to partner with EBR to produce this exclusive event supplement. Whether in a digital environment or face-to-face, our mission is to continue to connect the international life science community across more than 60 nations. It is crucial to ensure continued deal flow and drive the innovation that could ultimately improve healthcare globally. The collaboration between pharma and biotech confirms exactly the vision of EBD Group’s events, which began bringing pharma and biotech companies together in the early 1990s. Our commitment to bringing our community together to help facilitate medical breakthroughs is now more important than ever. In 2020, the BIO-Europe event series pioneered a successful switch to digital, while continuing to provide value to the life science community, and we’ll do it again next month. Taking place over four days, 25-28 October 2021, the event will bring together more than 3,500 executives from biotechnology, pharmaceuticals, and finance companies from around the world, who will engage in more than 15,000 partnering meetings.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pam Putz Managing Director, EBD Group
spacer
Pam Putz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera to build state-of-the-art manufacturing facility in Poland to serve more customers and patients

Based in Szczecin, this facility extends Nemera’s manufacturing capabilities and will bring more drug delivery device solutions to patients. Following the dynamic growth of the drug delivery devices market, as a world leader, Nemera is thrilled to extend its manufacturing capabilities in Poland.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement